TorreLABrayFSiegelRLet al. Global cancer statistics, 2012. CA Cancer J Clin2015; 65:87-108.
2.
Marcos-GrageraRMalloneSKiemeneyLAet al. Urinary tract cancer survival in Europe 1999-2007: Results of the population-based study EUROCARE-5. Eur J Cancer2015;51:2217-30.
3.
AIRTUM Working Group. La sopravvivenza dei pazienti oncologici in Italia. Epidemiologia e Prevenzione. Suppl. 1 n. 2. Marzo-Aprile 2017.
4.
FeldmanARKesslerLMyersMHNaughtonMD.The prevalence of cancer. Estimates based on the Connecticut Tumor Registry. N Engl J Med1986; 315:1394.
5.
VercelliMQuagliaAParodiSCrosignaniP.Cancer prevalence in the elderly. ITAPREVAL Working Group. Tumori1999; 85:391.
ScosyrevENoyesKFengCMessingE.Sex and racial differences in bladder cancer presentation and mortality in the US. Cancer2009; 115:68-74.
8.
HinotsuSAkazaHMikiTet al. Bladder cancer develops 6 years earlier in current smokers: analysis of bladder cancer registry data collected by the cancer registration committee of the Japanese Urological Association. Int J Urol2009; 16:64-69.
9.
VaidyaASolowayMSHawkeCet al. De novo muscle invasive bladder cancer: is there a change in trend?J Urol2001; 165 (1): 47-50.
10.
Linee Guida AIOM dei tumori uroteliali2017.
11.
FreedmanNDSilvermanDTHollenbeckARet al. Association between smoking and risk of bladder cancer among men and women. JAMA2011; 306 (7): 737-45.
12.
PietzakEJMucksavagePGuzzoTJMalkowiczSB.Heavy cigarette smoking and aggressive bladder cancer at initial presentation. Urology2015; 86:968-72.
13.
KogevinasM‘t MannetjeACordierSet al. Occupation and bladder cancer among men in Western Europe. Cancer Causes Control2003; 14:907-14.
14.
SteineckGPlatoNNorellSEHogstedtC.Urothelial cancer, some industry-related chemicals: an evaluation of the epidemiologic literature. Am J Ind Med1990; 17:371-91.
15.
ChevrierCJunodBCordierS.Does ozonation of drinking water reduce the risk of bladder cancer?Epidemiology2004; 15:605-14.
16.
Some drinking-water disinfectants and contaminants, including arsenic. IARC (International Agency for Research on Cancer) Working Group on the Evaluation of carcinogenic risks to humans. IARC Monograf Eval Carcinog Risks Hum2004; 84: 1-477.
17.
MarshallGFerreccioCYuanYet al. Fifty-year study of lung and bladder cancer mortality in Chile related to arsenic in drinking water. J Natl Cancer Inst2007; 99:920-8.
ZelefskyMJHousmanDMPeiXet al. Incidence of secondary cancer development after high-dose intensity-modulated radiotherapy and image-guided brachytherapy for the treatment of localized prostate cancer. Int J Radiat Oncol Biol Phys2012;83(3):953-9.
20.
TravisLBCurtisREGlimeliusBet al. Bladder and kidney cancer following cyclophosphamide therapy for non-Hodgkin’s lymphoma. J Natl Cancer Inst1995; 87:524-30.
21.
Al-ZalabaniAHStewartKFWesseliusAScholsAMZeegersMP. Modifiable risk factors for the prevention of bladder cancer: a systematic review of meta-analyses. Eur J Epidemiol2016;31(9):811-51.
22.
AbenKKWitjesJASchoenbergMPHulsbergen-van de KaaCVerbeekALKiemeneyLA. Familial aggregation of urothelial cell carcinoma. Int J Cancer2002; 98(2):274-8.
23.
MalatsNBustosANascimentoCMet al. P53 as a prognostic marker for bladder cancer: a meta-analysis and review. Lancet Oncol2005; 6:678-86.
24.
CoteRJDunnMDChatterjeeSJet al. Elevated and absent pRb expression is associated with bladder cancer progression and has cooperative effects with p53. Cancer Res1998; 58(6):1090-4.
